<DOC>
	<DOCNO>NCT00003237</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug , give surgery , may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy , consist paclitaxel cisplatin , give surgery treat patient cancer esophagus stomach .</brief_summary>
	<brief_title>Combination Chemotherapy After Surgery Treating Patients With Cancer Esophagus Stomach</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate disease free survival overall survival patient adenocarcinoma esophagus , gastroesophageal junction , cardia receive post-operative adjuvant paclitaxel plus cisplatin . OUTLINE : Patients undergo esophagogastrectomies within 4-12 week prior study . Patients receive intravenous paclitaxel 3 hour day 1 , follow intravenous cisplatin . Treatment repeat every 21 day 4 course . Patients exhibit disease recurrence unacceptable toxic effect remove study . Patients follow every 3 month 2 year , every 6 month next 3 year , every 12 month thereafter . PROJECTED ACCRUAL : A total 55 patient accrue within 16 month .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven adenocarcinoma esophagus , gastroesophageal junction cardia T2N1 , T3 N , T4 N , negative margin Proximal distal margin resection must negative No metastasis Must within 412 week date surgery clinically without evidence localregional distant recurrence PATIENT CHARACTERISTICS : Age : 18 Performance Status : ECOG 01 Life Expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1,500/mm3 Platelet count least 120,000/mm3 Hepatic : SGOT great 2 time upper limit normal ( ULN ) Bilirubin great 2 time ULN Renal : Creatinine within institutional normal limit Cardiovascular : No New York Heart Association class III IV heart disease No symptomatic coronary artery disease No myocardial infarction within 6 month No clinically significant conduction system abnormalities second third degree heart block bundle branch block Neurologic : No symptomatic peripheral neuropathy No psychosis Other : Not pregnant nursing Effective contraceptive method must use fertile patient No significant hearing loss No concurrent uncontrolled infection medical illness No concurrent malignancy within 3 year , except : Nonmelanoma skin cancer Carcinoma situ cervix No history allergy drug contain cremophor No hypersensitivity E. coli derive protein PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : No prior chemotherapy No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy No concurrent radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>stage II gastric cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>